Levomycetin-Acri

Levomycetin-Acri: Russian antibiotic of the chloramphenicol group

Levomycetin-Akri, also known as chloramphenicol, is an antibiotic produced in Russia by the Akrikhin HFC company. It belongs to the pharmacological group of antibiotics of the chloramphenicol group.

Chloramphenicol is widely used in medicine to treat various infections. It is available in various dosage forms, including 5% and 2.5% liniments. The active substance in the medicine is chloramphenicol.

Levomycetin-Acri is used in the treatment of various diseases, including typhoid fever, typhus, paratyphoid fever, brucellosis, rickettsiosis, tularemia, dysentery, whooping cough, chlamydia, meningitis, brain abscess, pneumonia, sepsis, ostomyelitis, purulent-inflammatory skin diseases, purulent wounds , infected burns, cracked nipples and infectious eye diseases.

However, chloramphenicol-Acri has some contraindications. It is not recommended for hypersensitivity to the drug, diseases of the hematopoietic organs, acute porphyria, severe renal and liver dysfunction, as well as psoriasis, eczema, fungal diseases, pregnancy, lactation and in early childhood (the first months of life).

When using chloramphenicol-Acri, side effects may occur, such as nausea, vomiting, loose stools, irritation of the mucous membranes of the mouth and pharynx, leukopenia, thrombocytopenia, reticulocytopenia, hypohemoglobinemia, agranulocytosis, anemia, psychomotor disorders, disturbances of consciousness, delirium, visual and auditory hallucinations , paralysis of the eyeballs, taste disturbance, decreased hearing and visual acuity, dysbacteriosis, superinfection, cardiovascular collapse, dermatitis and allergic reactions.

You must be careful when using chloramphenicol-Acri simultaneously with certain other drugs. For example, cycloserine can increase hematotoxicity, and phenobarbital can accelerate biotransformation and reduce the concentration and duration of effect. Levomycetin-Acri also has interactions with other drugs, such as cytostatics, You're welcome! If you have any more questions, feel free to ask.